News
Investor's Business Daily on MSN22m
Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease DrugBiohaven shares plunged Thursday after the Food and Drug Administration unexpectedly delayed the review date for its rare-disease drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback